Treatment or prophylaxis of thromboembolic disease in frail sufferers with cancer therefore requires a carefully tailored approach. or thromboembolism. Frailty in patients with cancer results from overlapping domains of aging, Eastern Cooperative Oncology Group (ECOG) status, type of cancer, poly-pharmacotherapy,
2013;(19):2048C2060
2013;(19):2048C2060. demonstrated a trend and only ERd. Furthermore, a stage 2 randomized research of lenalidomide and dexamethasone coupled with elotuzumab versus lenalidomide and dexamethasone without elotuzumab demonstrated promising results aswell [41].The median PFS figures were 9.9 months versus 6.8 months.